A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Zanidatamab (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms DiscovHER PAN-206
- Sponsors Jazz Pharmaceuticals Inc
- 25 Nov 2024 New trial record